Brief: Nykode Therapeutics Announces Strategic Repositioning Of VB10.16
Aug 21 (Reuters) - Nykode Therapeutics ASA NYKD.OL :
* NYKODE THERAPEUTICS ANNOUNCES STRATEGIC REPOSITIONING OF
VB10.16
TO FOCUS ON LOCALLY ADVANCED CERVICAL CANCER AND RECURRENT
METASTATIC HEAD AND NECK CANCER
* NYKODE THERAPEUTICS ASA - DECISION IS EXPECTED TO REDUCE
VB10.16
DEVELOPMENT COSTS BY OVER $25 MILLION
* NYKODE THERAPEUTICS ASA - DECIDED TO DISCONTINUE C-04
TRIAL
Source text for Eikon: ID:nObizwdjna
Further company coverage: NYKD.OL
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Nykode Therapeutics ASA
See all newsRCS - Accession Theraptcs. - Accession Therapeutics: Board appointments
Brief: Nykode Therapeutics Mulls Private Placement
Brief: Nykode Receives Draft Recommendation In Tax Case
Brief: Nykode Therapeutics Receives U.S. Vaccine Patent
Brief: Nykode Therapeutics Expects Draft Recommendation From Norwegian Tax Appeal Board In August 2026